<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016002</url>
  </required_header>
  <id_info>
    <org_study_id>Foscan 1/2005</org_study_id>
    <secondary_id>EUDRA CT 2005-004866-17</secondary_id>
    <nct_id>NCT01016002</nct_id>
  </id_info>
  <brief_title>Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma</brief_title>
  <official_title>A Phase II, Open-label, Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Salzburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biolitec Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Salzburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess efficacy and safety of Foscan (temoporfin)
      photodynamic therapy in the treatment of locally advanced perihilar bile duct carcinoma
      without distant metastases.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of local response and depth of tumoricidal tissue penetration of Foscan-PDT</measure>
    <time_frame>post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival time, overall survival time</measure>
    <time_frame>Before first intervention and at months 1, 3, 6, 9, 12, 18 and 24 after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity using WHO criteria and criteria for local toxicity in the biliary system</measure>
    <time_frame>Before first intervention and at months 1, 3, 6, 9, 12, 18 and 24 after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Non-curative Resectable Bile Duct Carcinoma</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temoporfin</intervention_name>
    <description>Drug treatment: Temoporfin 0.15 mg/kg body weight, intravenous injection within at least 6 min.
Laser Treatment: 652nm wavelength; 30 Joules/cm diffusor length ( 200 sec at 150mW/cm diffusor length), within 96 h after Foscan</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Foscan</other_name>
    <other_name>Meso-tetrahydroxyphenyl Chlorin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  bile duct carcinoma proven by histology in advanced or non-operable stage or tumor
             extension:

               1. Bismuth type III or IV ( not resectable with R0-margins )

               2. Bismuth type I or II, if resective surgery is contraindicated for old age or poor
                  surgical risk of patient

          -  sufficient general condition to undergo PDT (Karnofsky status &gt; 30%)

          -  age &gt; 19 years

          -  access to common bile duct (either via endoscopy after sphincterotomy or
             percutaneously after transhepatic drainage),

          -  informed written consent

        Exclusion Criteria:

          -  porphyria or other diseases exacerbated by light

          -  known intolerance or allergies to porphyrin derivatives

          -  a planned surgical procedure within the next 30 days

          -  coexisting ophthalmic disease likely to require slit lamp examination within the next
             30 days

          -  impaired kidney or liver function (creatinine &gt; 2.5x elevated, INR &gt; 2.2 on vitamin
             K),

          -  leukopenia ( WBC &lt; 2000/cmm ) or thrombopenia ( &lt; 50000/cmm ),

          -  cytotoxic chemotherapy within the past 4 weeks.

          -  pregnancy ( and safe contraception for 6 months after PDT )

          -  accompanying/complicating disease with very poor prognosis (expected survival &lt; 6
             weeks),

          -  proven advanced peritoneal carcinomatosis ( PET scan imaging, ascites positive for
             tumor cells)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frieder Berr, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine I, Paracelsus Medical University Salzburg, Muellner Hauptstrasse 48, 5020, Salzburg, Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lohse A, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frieder Berr, Prof., MD</last_name>
    <phone>(43-) 662-4482</phone>
    <phone_ext>2800</phone_ext>
    <email>f.berr@salk.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lohse A, Prof., MD</last_name>
    <phone>+49-(0)40-4280</phone>
    <phone_ext>33 910</phone_ext>
    <email>alohse@uke-uni-hamburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Internal Medicine I, Paracelsus Medical University Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frieder Berr, Prof., MD</last_name>
      <email>f.berr@salk.at</email>
    </contact>
    <investigator>
      <last_name>Frieder Berr, Prof., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Dept., University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Lohse, Prof., MD</last_name>
      <email>alohse@uke-uni-hamburg.de</email>
    </contact>
    <investigator>
      <last_name>A. Lohse, Prof., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>November 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>November 16, 2009</last_update_submitted>
  <last_update_submitted_qc>November 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Frieder Berr, M.D.</name_title>
    <organization>Department of Internal Medicine I, Paracelsus Medical University Salzburg, Muellner Hauptstrasse 48, 5020, Salzburg, Austria</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temoporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

